natgillin/translations-raw huggingface dataset:
Musculoskeletal and connective tissue disorders Very common Muscle spasm and cramps, musculoskeletal pain including myalgia9, arthralgia, 
Bolezni mišično-skeletnega sistema in vezivnega tkiva zelo pogosti mišični spazmi in krči, mišično-skeletne bolečine, vključno z mialgijo9, artralgijo in bolečinami v kosteh10
There is no experience in children and adolescents with CML below 2 years of age. 
Izkušenj pri otrocih s KML, mlajših od 2 let, ni.
Imatinib is also an inhibitor of the receptor tyrosine kinases for platelet-derived growth factor (PDGF), PDGF-R, and inhibits PDGF-mediated cellular events. 
Imatinib je tudi zaviralec receptorskih tirozin-kinaz za rastni faktor iz trombocitov (PDGF-plateletderived growth factor), PDGF-R in zavira celične dogodke, ki jih posreduje PDGF.
• Chronic renal failure 
• kronična odpoved ledvic.
Three large, international, open-label, non-controlled phase II studies were conducted in patients with Philadelphia chromosome positive (Ph+) CML in advanced blast or accelerated phase disease, other Ph+ leukaemias or with CML in the chronic phase but failing prior interferon-alpha (IFN) therapy. 
Opravili so tri velike mednarodne odprte nekontrolirane študije druge faze pri bolnikih s KML, s prisotnim kromosomom Philadelphia (Ph+), v napredovali, blastni ali pospešeni fazi bolezni, z drugimi Ph+ levkemijami ali s KML v kronični fazi, a po predhodnem neuspešnem zdravljenju z interferonom alfa (IFN).
The estimated rate of patients free of progression to accelerated phase or blast crisis at 84 months was significantly higher in the Imatinib arm compared to the IFN arm (92.5% versus 85.1%, p<0.001). 
Ocenjeni odstotek bolnikov, ki niso napredovali v pospešeno fazo ali blastno krizo pri 84 mesecih, je bil bistveno večji na kraku z zdravilom Imatinib Accord v primerjavi s krakom z IFN (92,5 % proti 85,1 %, p < 0,001).
Similar findings were found based on a 18-months landmark analysis. 
Izsledki so bili podobni, če so odziv in število transkriptov ocenjevali pri 18 mesecih.
Uncommon (may affect up to 1 in 100 people) or rare (may affect up to 1 in 1,000 people) 
Občasni (pojavijo se lahko pri največ 1 od 100 bolnikov) ali redki (pojavijo se lahko pri največ 1 od 1.000 bolnikov)
Seven years after the last patient had been recruited, the median duration of first-line treatment was 82 and 8 months in the Imatinib and IFN arms, respectively. 
Sedem let po vključitvi zadnjega bolnika je bilo mediano trajanje zdravljenja z zdravili prvega izbora v kraku z zdravilom Imatinib Accord 82 mesecev, v kraku z IFN pa 8 mesecev.
Table 3 Response in adult CML studies Study 0110 37-month data Chronic phase, IFN failure (n=532) 
Študija 0110 podatki pri 37 mesecih kronična faza, neuspeh IFN (n=532)
This phase III study in adult patients compared treatment with either single-agent Imatinib or a combination of interferon-alpha (IFN) plus cytarabine (Ara-C). 
V tej študiji tretje faze z odraslimi bolniki so primerjali zdravljenje z zdravilom Imatinib Accord kot edinim zdravilom na eni strani in s kombinacijo interferona alfa (IFN) s citarabinom (Ara-C) na drugi strani.
The starting dose is 100 mg, to be taken as one tablet of 100 mg once a day. 
Začetni odmerek je 100 mg, kar vzamete kot eno tableto po 100 mg enkrat na dan.
Patients with mild and moderate impairment of renal function appear to have a higher plasma exposure than patients with normal renal function. 
Kaže, da je pri bolnikih z blago in zmerno okvaro v delovanju ledvic izpostavljenost imatinibu v plazmi višja kot pri bolnikih znormalnim delovanjem ledvic.
• Muscle weakness and spasms with an abnormal heart rhythm (signs of changes in the amount of potassium in your blood). 
• oslabelost mišic in mišični spazmi z nepravilnim ritmom bitja srca (znaki spremenjenih vrednosti kalija v krvi),
Imatinib Accord is indicated for the treatment of 
Zdravilo Imatinib Accord je indicirano za zdravljenje
There was a significant increase in exposure to imatinib (the mean Cmaxand AUC of imatinib rose by 26% and 40%, respectively) in healthy subjects when it was co-administered with a single dose of ketoconazole (a CYP3A4 inhibitor). 
Pri zdravih osebah se je izpostavljenost imatinibu značilno povečala (povprečna Cmax in AUC imatiniba sta se povečali za 26 % oziroma 40 %), kadar je bil uporabljen z enim samim odmerkom ketokonazola (zaviralec CYP3A4).
• adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFRα rearrangement. 
• odraslih bolnikov z napredovalim hipereozinofilnim sindromom (HES) ali s kronično eozinofilno levkemijo (CEL) s premestitvijo FIP1L1-PDGFR ali z obojim;
1200 to 1600 mg (duration varying between 1 to 10 days): Nausea, vomiting, diarrhoea, rash, erythema, oedema, swelling, fatigue, muscle spasms, thrombocytopenia, pancytopenia, abdominal pain, headache, decreased appetite. 
Odmerki od 1200 do 1600 mg (trajanje zdravljenja od 1 do 10 dni): navzea, bruhanje, driska, izpuščaj, eritem, edemi, otekanje, utrujenost, mišični spazmi, trombocitopenija, pancitopenija, bolečine v trebuhu, glavobol, zmanjšan tek.
Imatinib Accord 400 mg film-coated tablets are supplied in packs containing 10, 30, or 90 tablets, but these may not all be available in your country. 
Imatinib Accord 400 mg filmsko obložene tablete so na tržišču v škatlah po 10, 30 ali 90 tablet, vendar je možno, da na trgu v vaši državi ni vseh navedenih pakiranj.
• adult patients with relapsed or refractory Ph+ ALL as monotherapy. 
• odraslih bolnikov z relapsom ali neodzivno Ph+ ALL v monoterapiji;
If cytopenia is unrelated to leukaemia, reduce dose of Imatinib Accordto 400 mg. 3. 
Če citopenija ni povezana z levkemijo, zmanjšajte odmerek zdravila Imatinib Accord na 400 mg.
Patients with Renal impairment should be given the minimum starting dose. 
Bolniki z okvarjenim delovanjem ledvic naj prejmejo najmanjši priporočeni začetni odmerek.
Imatinib was administered intermittently in cohorts 1-5, with increasing duration and earlier start of imatinib from cohort to cohort; cohort 1 receiving the lowest intensitiy and cohort 5 receiving the highest intensity of imatinib (longest duration in days with continuous daily imatinib dosing during the first chemotherapy treatment courses). 
Bolnikom v kohortah 1-5 so zdravilo imatinib odmerjali intermitentno, pri čemer je bilo v vsaki nadaljnji kohorti trajanje zdravljenja daljše, začetek zdravljenja z zdravilom imatinib pa zgodnejši, tako da je bila v 1. kohorti intenzivnost zdravljenja z zdravilom imatinib najnižja, v 5. kohorti pa najvišja (najdaljše trajanje zdravljenja glede na število dni neprekinjenega enkrat dnevnega odmerjanja zdravila imatinib pri prvem poteku kemoterapije).
How much Imatinib Accord to take 
Koliko zdravila Imatinib Accord jemati
How to store Imatinib Accord Contents of the pack and other information 
Shranjevanje zdravila Imatinib Accord Vsebina pakiranja in dodatne informacije
Total bilirubin: > 1.5-3.0 ULN AST: any 
zmerna celotni bilirubin: > 1,5-3,0 IULN AST: kakršnakoli huda celotni bilirubin: > 3-10 IULN AST: kakršnakoli
Chronic myeloid leukaemia (CML). 
- s kronično mieloično levkemijo (KML).
Using this approach, the estimated cumulative response rates for first-line treatment with Imatinib improved from 12 months of therapy to 84 months of therapy as follows: CHR from 96.4% to 98.4% and CCyR from 69.5% to 87.2%, respectively. 
Na ta način pridobljene ocene kumulativnih stopenj odziva za zdravljenje z zdravilom Imatinib Accord kot zdravilom prvega izbora so med 12. in 84. mesecem zdravljenja pokazale izboljšanje in sicer: popolni hematološki odziv s 96,4 % na 98,4 % in popolni citogeneteični odziv z 69,5 % na 87,2 %.
Imatinib Accord is a treatment for adults for: 
Zdravilo Imatinib Accord je zdravilo za odrasle:
Additionally, partial cytogenetic response (PCyR) was observed in 16% for a MCyR of 81%. 
Poleg tega so zabeležili tudi delen citogenetični odziv (PCyR) pri 16 % bolnikov ob 81 % s pomembnim citogentičnim odzivom.
(1 h), days 28-31, 35-38, 42-45; 6-MP 60 mg/ m2 oral, days 26-46 
(1 ura), 28.-31., 35.-38., 42.-45. dan; 6-MP 60 mg/m2 peroralno, 26.-46. dan konsolidacijsko zdravljenje
Resume treatment with Imatinib Accord at 600 mg. 
Spet začnite zdravljenje z zdravilom Imatinib Accord z odmerkom 600 mg.
Daunorubicin 30 mg/ m2 i.v., days 1-3, 15-16; 
daunorubicin 30 mg/m2 i.v., 1.-3., 15.-16. dan;
Based on the recovery of compound(s) after an oral 14C-labelled dose of imatinib, approximately 81% 
Izločanje Na podlagi izločenih spojin(e) po peroralnem odmerku imatiniba, označenega s 14C, se je približno
In newly diagnosed chronic phase CML grade 4neutropenia (ANC < 0.5x109/1) and thrombocytopenia (platelet count < 10x109/1) were observed in 3.6% and < 1% of patients, respectively. 
V na novo diagnosticirani kronični fazi KML sta bili odkriti nevtropenija 4. stopnje (ANC  0,5 x 109/l) in trombocitopenija 4. stopnje ( 10 x 109/l) pri 3,6 % oziroma  1 % bolnikov.
6400 mg (single dose): One case reported in the literature of one patient who experienced nausea, vomiting, abdominal pain, pyrexia, facial swelling, decreased neutrophil count, increased transaminases. 
Odmerek 6400 mg (enkraten odmerek): V literaturi je opisan en primer pri enem bolniku, pri katerem je prišlo do navzee, bruhanja, bolečin v trebuhu, zvišane telesne temperature, otekanja v obraz, znižane koncentracije nevtrofilcev in zvišanja aminotransferaz.
MTX 12 mg intrathecal, day 1 Remission induction DEX 10 mg/ m2 oral, days 6-7, 13-16; 
MTX 12 mg intratekalno, 1. dan indukcija remisije DEX 10 mg/m2 peroralno, 6.-7., 13.-16. dan;
• Combination of a widespread severe rash, feeling sick, fever, high level of certain white blood cells or yellow skin or eyes (signs of jaundice) with breathlessness, chest pain/discomfort, severely decreased urine output and feeling thirsty etc. (signs of a treatment-related allergic reaction). 
• kombinacija razširjenega hudega izpuščaja, slabosti s siljenjem na bruhanje, povišane telesne temperature, visoke vrednosti nekaterih vrst belih krvnih celic ali rumene obarvanosti kože ali oči (znaka zlatenice) z zasoplostjo, bolečino/neugodjem v prsnem košu, izrazito zmanjšanim izločanjem urina in žejo itd. (znaki alergijske reakcije na zdravljenje);
This is because Imatinib Accord could cause hepatitis B to become active again, which can be fatal in some cases. 
- če ste kdaj bili ali ste sedaj okuženi z virusom hepatitisa B. Zdravilo Imatinib Accord namreč lahko povzroči ponovno aktivacijo hepatitisa B, kar utegne biti v nekaterih primerih smrtno nevarno.
If you have accidentally taken too many tablets, talk to your doctor straight away. 
Če ste vzeli večji odmerek zdravila Imatinib Accord, kot bi smeli Če ste pomotoma vzeli preveč tablet, se nemudoma posvetujte s svojim zdravnikom.
If you are being treated for HES/CEL 
- Če se zdravite zaradi HES/CEL
Your doctor will tell you exactly how many tablets of Imatinib Accord to take. 
Uporaba pri odraslih Zdravnik vam bo natančno povedal, koliko tablet zdravila Imatinib Accord morate jemati.
Myelodysplastic/myeloproliferative diseases (MDS/MPD). 
- z mielodisplastičnimi/mieloproliferativnimi boleznimi (MDS/MPD).
- if you experience bruising, bleeding, fever, fatigue and confusion when taking Imatinib Accord, contact your doctor. 
- Če se v obdobju, ko jemljete zdravilo Imatinib Accord, pri vas pojavijo modrice, krvavitev, povišana telesna temperatura, utrujenost in zmedenost, se posvetujte z zdravnikom.
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON FOR BLISTER 
PODATKI NA ZUNANJI OVOJNINI KARTONSKA ŠKATLA ZA PRETISNI OMOT
(q 12 h), days 2-3, for 4 cycles 
(na 12 ur), 2.-3. dan, v 4 ciklusih vzdrževanje
Overall, in patients receiving first-line Imatinib, the average daily dose delivered was 406 ± 76 mg. 
Povprečni odmerek v skupini vseh bolnikov, ki so prejemali zdravilo Imatinib Accord kot zdravilo prvega izbora, je bil 406 ± 76 mg na dan.
G-CSF = granulocyte colony stimulating factor, VP-16 = etoposide, MTX = methotrexate, IV = intravenous, SC = subcutaneous, IT = intrathecal, PO = oral, IM = intramuscular, ARA-C = cytarabine, CPM = cyclophosphamide, VCR = vincristine, DEX = dexamethasone, DAUN = daunorubicin, 6-MP = 6-mercaptopurine, E.Coli L-ASP = L-asparaginase, PEG-ASP = PEG asparaginase, MESNA= 2-mercaptoethane sulfonate sodium, iii= or until MTX level is < 0.1 μM, q6h = every 6 hours, Gy= Gray 
= intramuskularno, ARA-C = citarabin, CPM = ciklofosfamid, VCR = vinkristin, DEX = deksametazon, DAUN = daunorubicin, 6-MP = 6-merkaptopurin, E.Coli L-ASP = L-asparaginaza, PEG-ASP = PEG asparaginaza, MESNA= natrijev 2-merkaptoetan sulfonat, iii= oziroma dokler koncentracija MTX ni < 0,1 µM, Gy= Gray
This time-to-event endpoint is strongly affected by the high crossover rate from IFN+Ara-C to Imatinib. 
Na ta opazovani dogodek, ki se veže na čas do dogodka, je močno vplival velik delež bolnikov, ki so z zdravljenja z IFN+Ara-C prešli na zdravilo Imatinib Accord.
3 On a patient-year basis, cardiac events including congestive heart failure were more commonly observed in patients with transformed CML than in patients with chronic CML. 
3 Dogodke v zvezi s srcem, vključno s kongestivnim srčnim popuščanjem, so na podlagi enote bolnik-leto pogosteje opažali pri bolnikih s transformacijo KML kot pri bolnikih s kroničnim potekom KML.
The active substance imatinib demonstrates an environmental risk for sediment organisms. 
Učinkovina imatinib predstavlja tveganje za okolje, in sicer za organizme v usedlinah.
Imatinib Accord 100 mg film-coated tablets are supplied in packs containing 20, 60, 120 or 180 tablets, but these may not all be available in your country. 
Imatinib Accord 100 mg filmsko obložene tablete so na tržišču v škatlah po 20, 60, 120 ali 180 tablet, vendar je možno, da na trgu v vaši državi ni vseh navedenih pakiranj.
(1 h), days 1-5; VM26 60 mg/ m2 i.v. 
(1 ura), 1.-5. dan; VM26 60 mg/m2 i.v.
• Rash, red skin with blisters on the lips, eyes, skin or mouth, peeling skin, fever, raised red or purple skin patches, itching, burning sensation, pustular eruption (signs of skin problems). 
• izpuščaj, rdeča koža z mehurčki na ustnicah, očeh, koži ali v ustih, luščenje kože, povišana telesna temperatura, rdeče ali vijolične lise nad nivojem kože, srbenje, pekoč občutek, gnojni izpuščaj (znaki težav s kožo),
Accelerated phase is defined by the presence of any of the following: blasts ≥ 15% but < 30% in blood or bone marrow, blasts plus promyelocytes ≥ 30% in blood or bone marrow (providing < 30% blasts), peripheral blood basophils ≥ 20%, platelets < 100 x 109/l unrelated to therapy. 
Pospešeno fazo opredeljuje eno ali več sledečih meril: blasti v krvi ali kostnem mozgu ≥ 15 %, vendar < 30 %, blasti in promielociti skupaj ≥ 30 % v krvi ali kostnem mozgu (pogoj: blasti < 30 %), bazofilci v periferni krvi ≥ 20 %, trombociti < 100 x 109/l ne glede na zdravljenje.
Hypromellose 6 cps (E464) Microcrystalline cellulose pH 102 Crospovidone 
Jedro tablete hipromeloza 6 cps (E464) mikrokristalna celuloza pH 102 krospovidon brezvodni koloidni silicijev dioksid magnezijev stearat
Patients with renal dysfunction or on dialysis should be given the minimum recommended dose of 400 mg daily as starting dose. 
Bolniki z okvarjenim delovanjem ledvic ali bolniki na dializi naj za začetni odmerek prejmejo najmanjši priporočeni odmerek 400 mg na dan.
Patients with Severe renal impairment should be treated with caution. 
Pri zdravljenju bolnikov s hudo okvarjenim delovanjem ledvic je potrebna previdnost.
Blood amylase increased * These types of reactions have been reported mainly from post-marketing experience with Imatinib. 
* O teh vrstah neželenih učinkov so poročali večinoma v okviru izkušenj v obdobju trženja zdravila z zdravilom Imatinib.
However, the occurrence of cytopenias was also clearly dependent on the stage of the disease, the frequency of grade 3 or 4 neutropenias (ANC < 1.0x109/1) and thrombocytopenias (platelet count < 50x109/1) being between 4 and 6 times higher in blast crisis and accelerated phase (59-64% and 44-63% for neutropenia and thrombocytopenia, respectively) as compared to newly diagnosed patients in chronic phase CML (16.7% neutropenia and 8.9% thrombocytopenia). 
Nevtropenija 3. ali 4. stopnje (ANC  1,0 x 109/l) in trombocitopenija (koncentracija trombocitov  50 x 109/l) sta bili štirikrat do šestkrat pogostejši v blastni krizi in pospešeni fazi (nevtropenija 59-64 % in trombocitopenija 44-63 %) kot pri na novo diagnosticiranih bolnikih v kronični fazi KML (nevtropenija 16,7 % in trombocitopenija 8,9 %).
Caution should be used when taking imatinib with protease inhibitors, azole antifungals, certain macrolides (see section 4.5), CYP3A4 substrates with a narrow therapeutic window (e.g. cyclosporine, pimozide, tacrolimus, sirolimus, ergotamine, diergotamine, fentanyl, alfentanil, terfenadine, bortezomib, docetaxel, quinidine) or warfarin and other coumarin derivatives (see section 4.5). 
Previdnost je potrebna pri uporabi imatiniba z zaviralci proteaze, azolnimi antimikotiki, določenimi makrolidi (glejte poglavje 4.5), s substrati CYP3A4 z ozkim terapevtskim oknom (na primer s ciklosporinom, pimozidom, takrolimusom, sirolimusom, ergotaminom, diergotaminom, fentanilom, alfentanilom, terfenadinom, bortezomibom, docetakselom, kinidinom) ali z varfarinom in drugimi derivati kumarina (glejte poglavje 4.5).
Talk to your doctor before taking Imatinib Accord: - if you have or have ever had a liver, kidney or heart problem. 
Opozorila in previdnostni ukrepi Pred začetkom jemanja zdravila Imatinib Accord se posvetujte z zdravnikom: - če imate ali ste kdaj imeli težave z jetri, ledvicami ali srcem; - če jemljete zdravilo levotiroksin, ker so vam odstranili ščitnico.
In study I2301, a total of 93 paediatric, adolescent and young adult patients (from 1 to 22 years old) with Ph+ ALL were enrolled in an open-label, multicentre, sequential cohort, nonrandomized phase III trial, and were treated with imatinib (340 mg/m2/day) in combination with intensive chemotherapy after induction therapy. 
V odprto, nerandomizirano, multicentrično preizkušanje faze III z oznako I2301 in z zaporednimi kohortami so vključili skupno 93 otrok, mladostnikov in mladih odraslih (starih od 1 do 22 let) s Ph+ ALL in jih zdravili z zdravilom imatinib (340 mg/m2/dan) v kombinaciji z intenzivno kemoterapijo po indukcijskem zdravljenju.
INFORMATION IN BRAILLE Imatinib Accord 400 mg 
PODATKI V BRAILLOVI PISAVI Imatinib Accord 400 mg
Substances that inhibit the cytochrome P450 isoenzyme CYP3A4 activity (e.g. protease inhibitors such as indinavir, lopinavir/ritonavir, ritonavir, saquinavir, telaprevir, nelfinavir, boceprevir; azole antifungals including ketoconazole, itraconazole, posaconazole, voriconazole; certain macrolides such as erythromycin, clarithromycinand telithromycin) could decrease metabolism and increase imatinib concentrations. 
Snovi, ki zavirajo aktivnost izoencima CYP3A4 citokroma P450 (na primer zaviralci proteaze, kot so indinavir, lopinavir/ritonavir, ritonavir, sakvinavir, telaprevir, nelfinavir, boceprevir; azolni antimikotiki vključno s ketokonazolom, itrokonazolom, posakonazolom, vorikonazolom; določenimi makrolidi kot so eritromicin, klaritromicin in telitromicin), bi lahko zmanjševale presnovo in zviševale koncentracije imatiniba.
Very common (may affect more than 1 in 10 people) or common (may affect up to 1 in 10 people) 
Zelo pogosti (pojavijo se lahko pri več kot 1 od 10 bolnikov) ali pogosti (pojavijo se lahko pri največ 1 od 10 bolnikov)
Hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL). 
- s hipereozinofilnim sindromom (HES) ali kronično eozinofilno levkemijo (CEL) ali z obojim.
INFORMATION IN BRAILLE Imatinib Accord 100 mg 
PODATKI V BRAILLOVI PISAVI Imatinib Accord 100 mg
There is limited experience in children and adolescents with Ph-positive ALL and very limited experience in children and adolescents with MDS/MPD, DFSP and HES/CEL. 
Izkušenj pri otrocih in mladostnikih s Ph pozitivno ALL je malo, pri otrocih in mladostnikih z MDS/MPD, DFSP ali s HES/CEL pa zelo malo.
• adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. 
• odraslih in pediatričnih bolnikov z na novo diagnosticirano kronično mieloično levkemijo (KML), s prisotnim kromosomom Philadelphia (bcr-abl) (Ph+), pri katerih presaditev kostnega mozga kot zdravljenje prve izbire ne pride v poštev;
Similar results were observed in patients with malignant gliomas treated with imatinib while taking enzyme-inducing anti-epileptic drugs (EIAEDs) such as carbamazepine, oxcarbazepine and phenytoin. 
Podobne rezultate so opažali pri bolnikih z malignim gliomom, ki so jih zdravili z imatinibom, sočasno pa so jemali tudi antiepileptična zdravila, ki inducirajo encime.
Ara-C 1,000 mg/m2/12h i.v. 
Ara-C 1.000 mg/m2/12 ur i.v.
The dose of 340 mg/m2 daily is recommended for children and adolescents with chronic phase CML and advanced phase CML (not to exceed the total dose of 800 mg). 
Za otroke in mladostnike s kronično fazo KML oziroma z napredovalimi fazami KML je priporočeni odmerek 340 mg/m2 na dan (ne sme preseči celotnega odmerka 800 mg).
Active substances that may decrease imatinib plasma concentrations 
Učinkovine, ki lahko znižajo plazemske koncentracije imatiniba:
If cytopenia persists for 4 weeks and is still unrelated to leukaemia, stop Imatinib Accord until ANC ≥ 1 x 109/1 and platelets ≥ 20 x 109/1, then resume treatment at 300 mg. 
Če citopenija vztraja 4 tedne in še vedno ni povezana z levkemijo, prekinite zdravljenje z zdravilom Imatinib Accord, dokler ni ANC  1 x 109/l in koncentracija trombocitov  20 x 109/l, nato spet začnite zdravljenje z odmerkom 300 mg.
• Muscle spasms with a fever, red-brown urine, pain or weakness in your muscles (signs of muscle problems). 
• mišični spazmi z vročino, rdeče-rjavo obarvan urin, boleče ali oslabele mišice (znaki težav z mišicami),
The same publication reported long term follow-up data from 12 MDS/MPD patients with PDGFR 
V isti publikaciji poročajo o podatkih z dolgoročnih kontrolnih pregledov za 12 bolnikov z MDS/MPD s preureditvijo gena za PDGFR (5 bolnikov iz študije B2225).
There is very limited experience in children and adolescents with MDS/MPD, DFSP and HES/CEL. 
Izkušenj pri otrocih in mladostnikih z MDS/MPD, DFSP ali s HES/CEL pa zelo malo.
Thisinhibition has not been observed in vivoafter the administration of imatinib 400 mg and paracetamol 1000 mg. Higher doses of imatinib and paracetamol have not been studied. 
Tega zaviranja po uporabi imatiniba 400 mg in paracetamola 1000 mg in vivo niso opažali.
If cytopenia persists for 4 weeks and is still unrelated to leukaemia, stop Imatinib Accord until ANC ≥ 1x109/1 and platelets ≥ 20x109/1, then resume treatment at 200 mg/m2. 
Če citopenija vztraja 4 tedne in še vedno ni povezana z levkemijo, prekinite zdravljenje z zdravilom Imatinib Accord, dokler ni ANC  1 x 109/l in koncentracija trombocitov  20 x 109/l, nato spet začnite zdravljenje z odmerkom 200 mg/m2.
Resume treatment with Imatinib Accord at previous dose (i.e. before severe adverse reaction). 
Spet začnite zdravljenje z zdravilom Imatinib Accord s prejšnjim odmerkom (t.j.
Pretreatment with multiple doses of rifampicin 600 mg followed by a single 400 mg dose ofimatinibresulted in decrease in Cmax and AUC(0-∞) by at least 54% and 74%, of the respective values without rifampicin treatment. 
400-miligramski odmerek imatiniba, je povzročilo zmanjšanje Cmax oziroma AUC(0-∞) za vsaj 54 % oziroma 74 % zadevnih vrednosti brez zdravljenja z rifampicinom.
How to take Imatinib Accord 
Kako jemati zdravilo Imatinib Accord
Patients had received a median of 14 months of prior IFN therapy at doses ≥ 25 x 106 IU/week and were all in late chronic phase, with a median time from diagnosis of 32 months. 
mesecev, bolniki pa so bili vsi v pozni kronični fazi s povprečnim časom 32 mesecev od postavitve diagnoze.
Patients on imatinib treatment who are concerned about their fertility should consult with their physician. 
Bolniki, ki jih skrbi glede njihove plodnosti v času zdravljenja z zdravilom Imatinib Accord, naj se posvetujejo s svojim zdravnikom.
Not applicable. 
se smiselno ne uporablja